Using DNA samples obtained from two unrelated patients, diagnosed as having familial dysalbuminaemic hyperthyroxinaemia (FDH), exons 1-14 which span the entire coding region of the human serum albumin (HSA) gene were amplified by the polymerase chain reaction. The sequence of each of the 14 DNA fragments was then determined. In each case a point mutation was identified at nucleotide 653 which causes an Arg to His substitution at amino acid position 218 The major hazard for FDH patients is that they can be misdiagnosed as hyperthyroid and subjected to unwarranted treatment. ' The raised serum TT4 in FDH patients results from the presence of an abnormal human serum albumin (HSA) which exhibits enhanced binding to thyroxine (T4).28 Our study on intrinsic fluorescence properties of purified normal HSA and HSA obtained from an FDH patient, hereafter referred to as patient 1, using both steady state and time resolved methodologies, showed that the patient had two HSA species with different affinities for T4.9 Until now the specific molecular defect of FDH HSA was unknown. This study describes a specific amino acid substitution resulting from the same nucleotide change in the HSA gene in two unrelated FDH patients.
Familial dysalbuminaemic hyperthyroxinaemia (FDH) is an autosomal dominant syndrome in which, although patients have a raised total serum thyroxine concentration (TT4), they are clinically euthyroid.'2 The euthyroid state of FDH patients is confirmed by normal serum levels of free thyroxine (FT4), thyroid stimulating hormone, and triiodothyronine.2 The prevalence of FDH has been estimated in our earlier study2 to be about 4% of hyperthyroxinaemic patients. The two FDH patients discussed in this paper are new case findings, unrelated to our previous study. 2 The major hazard for FDH patients is that they can be misdiagnosed as hyperthyroid and subjected to unwarranted treatment. ' The raised serum TT4 in FDH patients results from the presence of an abnormal human serum albumin (HSA) which exhibits enhanced binding to thyroxine (T4).28 Our study on intrinsic fluorescence properties of purified normal HSA and HSA obtained from an FDH patient, hereafter referred to as patient 1, using both steady state and time resolved methodologies, showed that the patient had two HSA species with different affinities for T4.9 Until now the specific molecular defect of FDH HSA was unknown. This study describes a specific amino acid substitution resulting from the same nucleotide change in the HSA gene in two unrelated FDH patients.
We have developed a rapid method for identifying FDH patients with the mutation we describe by using polymerase chain reaction (PCR) amplification of exon 7 of the HSA gene followed by restriction endonuclease digestion and gel electrophoresis.
Materials and methods

SOURCE OF WHOLE BLOOD
Whole blood drawn up in EDTA was obtained from patient 1 and patient 2, diagnosed as FDH by methods described previously.2
Whole blood was also obtained from a normal volunteer.
PURIFICATION OF NORMAL AND FDH HSA
HSA was purified from the plasma of patient 1 and the normal volunteer using identical methods. Ammonium sulphate was added to the plasma to 50% saturation. HSA was precipitated from the supernatant solution by lowering the pH to 4-4 at 2°C. The precipitate was dissolved in water and the lipid removed by reaction with Norit A activated charcoal at pH 3-0 followed by dialysis in water. The HSA was further purified by affinity chromatography using cibracon blue linked to sepharose CL-6B (Sigma).'0 The matrix was equilibrated in 0 04 mol/l sodium phosphate, pH 7 5, 0 15 mol/l NaCl (PBS). After washing the column with PBS, the bound HSA was eluted with 3 mol/l NaCl. The eluent was dialysed in water. The purity of the HSA was determined by SDS-PAGE." TRYPTIC DIGESTION OF HSA Purified HSA from patient 1 and purified commercial HSA (Sigma, fatty acid free, globulin free) dissolved in water were lyophylised and treated identically.
The purified HSA was reduced and alkylated to pyridyl-ethyl cystinyl HSA (PEC-HSA)'2 and desalted by preparative C-8 reverse phase high pressure liquid chromatography (HPLC) (0-1% trifluoroacetic acid to acetonitrile). The desalted PEC-HSA was digested with trypsin (2%) in 100 mmol/l sodium bicarbonate, 2 mol/I urea, 1 mmol/l calcium chloride, pH 8- A set of two 24 base pair primers were chosen to be complementary to known intron DNA sequences"5 on either side of each of the 14 coding exons of HSA. Fragments containing each exon were generated using PCR. For exon 7 which contains the point mutation the following oligonucleotide primers were used: 5' oligonucleotide: 5' CTGCCCTAAGGA-TAAGTGATTACC 3' (intron 6) 3' oligonucleotide: 5' ATTCTACCAACTT-GAGCATGCAAG 3' (intron 7). After amplification each fragment was separated from other reaction components (Qiagen, PCR Purification Spin Kit). The fragments were sequenced directly using the same primers as those used for amplification (Promega, fM Sequencing System).
All 14 exons were amplified and sequenced from genomic DNA purified from patient 1 and the normal volunteer. Corresponding termination reactions from each person were loaded next to each other in electrophoresis. The corresponding lanes were scanned for any sequence variation between the two subjects. Only exon 7 was amplified and sequenced for the second FDH patient (patient 2) to verify a mutation found in that exon in patient 1.
HPHI DIGESTION OF EXON 7 CONTAINING
FRAGMENT DNA fragments containing exon 7 were generated by the same procedure used for sequencing. The fragment containing exon 7 from a normal HSA gene does not contain an HphI site whereas a mutation identified in both FDH patients creates an HphI site. The amplification product was precipitated in 75% absolute ethanol and resuspended in 20 il of HphI digestion buffer. Ten units of HphI (New England Biolabs) was added and the reaction was incubated for six hours at 37°C. For each sample a control was incubated without HphI.
Samples were electrophoresed in a 3% agarose (FMC BioProducts, Metaphor Agarose) gel in 1 x TAE (0-04 mol/l Tris-acetate, 0 00 1 mol/l EDTA, pH 8-0) and bands were visualised by staining with ethidium bromide.
ASSESSMENT OF HSA BINDING IN THE ABSENCE OF OTHER SERUM COMPONENTS
The binding properties of HSA from the normal volunteer and patient 1 were compared by using a radioimmunoassay kit (Clinical Assays, Stillwater, MN) designed to measure the free T4 level in serum samples. Commercial HSA was also assayed as a control. The assay is designed to measure free T4 by competitive binding. T4 antibody is immobilised on the lower inner surface of a tube. A serum sample is added along with a fixed amount of an ['25I]T4 tracer. The tracer and the free T4 in the serum sample compete for binding sites on the antibody giving an inverse correlation between free T4 concentration and radioactivity associated with antibody.
The assay was adapted to measure HSA affinity for the T4 tracer as follows. To each assay tube 1 ml of tracer buffer and the T4 tracer were added followed by 250 ig of HSA in 50 jtl H20. The tubes were incubated for 90 minutes at 37°C and the fluid was aspirated. The amount of radioactivity remaining bound to the assay tubes was measured in a Iso-Data gamma counter.
Results
AMPLIFICATION AND SEQUENCING OF PCR FRAGMENTS
DNA fragments containing exons 1-14, which span the entire coding region of the HSA gene, were successfully amplified and sequenced using genomic DNA obtained from the normal volunteer and patient 1. The sequence obtained for the normal volunteer matched a previously published HSA sequence'5 at all coding nucleotides. Sequence obtained from patient 1 matched the sequence at all positions except for a G to A transition at nucleic acid position 653 (fig 1) causing an Arg(CGC) to His(CAC) substitution at amino acid position 218 in mature HSA.
Although an adenosine appears at position 653 in the FDH sequence the guanosine is still present but at half the intensity of the corresponding guanosine in the normal sample. This indicates that the condition is heterozygous as the PCR fragment represents an amplification of both alleles. The mutation was verified by observing a C to T transition on the opposite strand (fig 1) . Amplification and sequencing of exon 7 using genomic DNA obtained from patient 2 gave a result for exon 7 identical to that of patient 1.
HPHI DIGESTION OF EXON 7 CONTAINING FRAGMENT
The exon 7 containing DNA fragments from both FDH patients were subjected to HphI digestion. Only partial digestion was observed for both heterozygotes, as expected (fig 2) . A 
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